Literature DB >> 33860394

Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series.

Russo Cinzia Valeria1, Lanzillo Roberta2, Saccà Francesco2, Moccia Marcello2, Carotenuto Antonio2, Brescia Morra Vincenzo2.   

Abstract

Data on pregnancy outcome in alemtuzumab-treated women are scarce and derived from safety reports of clinical trials. We report on seven women with overall eight pregnancies during treatment with alemtuzumab in a real-world setting. All pregnancies occurred within 9 months after alemtuzumab treatment, and two of them within 4 months despite patients being informed on pregnancy prevention. We found one congenital cytomegalovirus infection, one spontaneous abortion, one elective abortion due to extrauterine pregnancy, and five live births without congenital abnormalities or birth defects.
© 2020. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Alemtuzumab; Breastfeeding; Cytomegalovirus; Disease modifying treatment; Multiple sclerosis; Pregnancy

Year:  2021        PMID： 33860394     DOI： 10.1007/s10072-020-04975-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  7 in total

Review 1.  Pregnancy and multiple sclerosis.

Authors:  O Abramsky
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

2.  Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Authors:  A J Coles; E Fox; A Vladic; S K Gazda; V Brinar; K W Selmaj; A Skoromets; I Stolyarov; A Bass; H Sullivan; D H Margolin; S L Lake; S Moran; J Palmer; M S Smith; D A S Compston
Journal:  Neurology       Date:  2012-03-21       Impact factor: 9.910

3.  Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Authors:  Emilio Portaccio; Pietro Annovazzi; Angelo Ghezzi; Mauro Zaffaroni; Lucia Moiola; Vittorio Martinelli; Roberta Lanzillo; Vincenzo Brescia Morra; Francesca Rinaldi; Paolo Gallo; Carla Tortorella; Damiano Paolicelli; Carlo Pozzilli; Laura De Giglio; Paola Cavalla; Eleonora Cocco; Maria Giovanna Marrosu; Francesco Patti; Claudio Solaro; Paolo Bellantonio; Antonio Uccelli; Alice Laroni; Luisa Pastò; Marta Giannini; Maria Trojano; Giancarlo Comi; Maria Pia Amato
Journal:  Neurology       Date:  2018-02-07       Impact factor: 9.910

4.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

5.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

6.  Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Authors:  Eva Havrdova; Douglas L Arnold; Jeffrey A Cohen; Hans-Peter Hartung; Edward J Fox; Gavin Giovannoni; Sven Schippling; Krzysztof W Selmaj; Anthony Traboulsee; D Alastair S Compston; David H Margolin; Karthinathan Thangavelu; Claudio E Rodriguez; Darlene Jody; Richard J Hogan; Panos Xenopoulos; Michael A Panzara; Alasdair J Coles
Journal:  Neurology       Date:  2017-08-23       Impact factor: 9.910

7.  Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Authors:  Alasdair J Coles; Jeffrey A Cohen; Edward J Fox; Gavin Giovannoni; Hans-Peter Hartung; Eva Havrdova; Sven Schippling; Krzysztof W Selmaj; Anthony Traboulsee; D Alastair S Compston; David H Margolin; Karthinathan Thangavelu; Madalina C Chirieac; Darlene Jody; Panos Xenopoulos; Richard J Hogan; Michael A Panzara; Douglas L Arnold
Journal:  Neurology       Date:  2017-08-23       Impact factor: 9.910
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.